Diagnosing prostate cancer in asymptomatic patients

Bradley, Stephen H; Funston, Garth; Jones, Daniel; Watson, Jessica

doi:10.1136/bmj-2022-071076

Cited by 9 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We thank Booth and colleagues for their comments 1. As we outlined in our editorial,2 we agree that the use of magnetic resonance imaging has been an important development which has reduced the need for biopsy along with its associated harms. While we did not offer an opinion as to whether a programme of prostate cancer screening should be instituted, the evidence we cited in the editorial suggests that the prospect of such a programme resulting in overall benefit is questionable 3…”

mentioning

confidence: 75%

Authors’ reply to Booth and colleagues

Bradley

Funston

Jones

et al. 2022

BMJ

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 75%

Authors’ reply to Booth and colleagues

Bradley

Funston

Jones

et al. 2022

BMJ

Self Cite

View full text Add to dashboard Cite

“…Most respondents thought that there was PSA screening for PCA in their countries based on the clinical knowledge that PSA is a first-line clinical test for patients suspected of or concerned with PCA in all countries. However, routine PSA screening tests for populations are not currently recommended because there has not yet been any benefit against PCA mortality, and PCA characteristics are heterogeneous [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Use of Imaging and Biopsy in Prostate Cancer Diagnosis: A Survey From the Asian Prostate Imaging Working Group

Wang,

Jinzaki,

Tan

et al. 2023

Korean J Radiol

View full text Add to dashboard Cite

Objective To elucidate the use of radiological studies, including nuclear medicine, and biopsy for the diagnosis and staging of prostate cancer (PCA) in clinical practice and understand the current status of PCA in Asian countries via an international survey. Materials and Methods The Asian Prostate Imaging Working Group designed a survey questionnaire with four domains focused on prostate magnetic resonance imaging (MRI), other prostate imaging, prostate biopsy, and PCA backgrounds. The questionnaire was sent to 111 members of professional affiliations in Korea, Japan, Singapore, and Taiwan who were representatives of their working hospitals, and their responses were analyzed. Results This survey had a response rate of 97.3% (108/111). The rates of using 3T scanners, antispasmodic agents, laxative drugs, and prostate imaging-reporting and data system reporting for prostate MRI were 21.6%–78.9%, 22.2%–84.2%, 2.3%–26.3%, and 59.5%–100%, respectively. Respondents reported using the highest b-values of 800–2000 sec/mm 2 and fields of view of 9–30 cm. The prostate MRI examinations per month ranged from 1 to 600, and they were most commonly indicated for biopsy-naïve patients suspected of PCA in Japan and Singapore and staging of proven PCA in Korea and Taiwan. The most commonly used radiotracers for prostate positron emission tomography are prostate-specific membrane antigen in Singapore and fluorodeoxyglucose in three other countries. The most common timing for prostate MRI was before biopsy (29.9%). Prostate-targeted biopsies were performed in 63.8% of hospitals, usually by MRI-ultrasound fusion approach. The most common presentation was localized PCA in all four countries, and it was usually treated with radical prostatectomy. Conclusion This survey showed the diverse technical details and the availability of imaging and biopsy in the evaluation of PCA. This suggests the need for an educational program for Asian radiologists to promote standardized evidence-based imaging approaches for the diagnosis and staging of PCA.

show abstract

“…This type of cancer is a complex and multifactorial cancer with no obvious clinical symptoms in the early stages. 3 Prostate-specific antigen (PSA), 4 secreted by normal prostate gland cells and prostate cancer cells, 5 is a serine protease with 244 amino acid residues and a relative molecular mass of 33 000–34,000 secreted by prostate follicular and ductal epithelial cells. 6 Under normal physiological conditions, it is present in prostate tissue, prostatic fluid, semen, serum and urine.…”

Section: Introductionmentioning

confidence: 99%